Pharsight

Tembexa is owned by Chimerix.

Tembexa contains Brincidofovir.

Tembexa has a total of 5 drug patents out of which 0 drug patents have expired.

Tembexa was authorised for market use on 04 June, 2021.

Tembexa is available in suspension;oral dosage forms.

Tembexa can be used as method of treating human smallpox disease.

The generics of Tembexa are possible to be released after 10 October, 2034.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9303051	CHIMERIX	Phosphonate ester derivatives and methods of synthesis thereof	Aug, 2031 (8 years from now)
US8962829	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10112909	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)
US10487061	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)
US9371344	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (11 years from now)